Human Umbilical Vein Endothelial Cells (HUVEC) Market
Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis By Type (Single Donors, Pooled Donors), By Application (Wound Healing, Angiogenesis, Oncology, Tissue Engineering), By Region - Global Insights 2021 to 2031
Key Questions Answered in Report
Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?
According to Fact.MR, the oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, attributed to their purported effectiveness in targeting malignant growth. Simultaneously, uptake across tissue culture is also likely to widen in the future.
Which countries are likely to offering promising expansion prospects for HUVEC through 2031?
The U.S. and Indian markets are expected to provide immense growth opportunities for HUVEC, as both countries are making significant strides in furthering good quality healthcare across key domains as CVD and cancer treatment.
Which prominent players are operating within the global HUVEC landscape?
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.
Avail customized purchase options for your needs
Human Umbilical Vein Endothelial Cells 2016 to 2020 Trends Vs Projections for 2021 to 2031
From 2016 to 2020, demand for human umbilical vein endothelial cell-based treatment has been gradually gaining momentum, as advancements in genetic engineering and biotechnology become increasingly overt. Extensive applications are being witnessed in the oncology domain, followed by tissue culture and angiogenesis.
Growth of the market remained consistent across the COVID-19 pandemic, although initial shocks were experienced in the first half of 2020, attributed to reduced hospital visits amid fears of contracting the novel coronavirus infection. Future prospects are extremely lucrative, especially across emerging economies across Asia as spending on healthcare infrastructure augments.
How is Surging Tissue Engineering Popularity Augmenting Adoption of Human Umbilical Vein Endothelial Cells?
Over the years, tissue engineering has acquired immense popularity, being deployed across a broad spectrum of treatment domains. Tissue engineering provides alternatives to surgical reconstruction, transplants, and other mechanical devices that are used to repair damaged tissues.
The market for tissue engineering is also driven by a continuous increase in the need for effective regenerative treatments owing to a rise in the prevalence of diabetes, obesity, and other disorders due to lifestyle changes, aging population, and growing trauma cases. Hence, demand for human umbilical vein endothelial cells based treatment is garnering significant momentum.
An Adaptive Approach to Modern-day Research Needs
What is the Scope of HUVEC in Angiogenesis?
Angiogenesis using human umbilical vein endothelial cells is proving highly beneficial to address hepatocellular carcinoma (HCC), a typical hyper-vascular tumour. Hepatocellular carcinoma is a debilitating form of liver cancer which typically arises post a severe Hepatitis B or C infection.
Hence, prominent healthcare providers are leveraging advanced treatment and diagnosis approaches to address this condition. Hepatocellular carcinoma is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly.
How Bright are HUVEC Growth Prospects across the U.S.?
HUVEC-based treatment adoption rate in the U.S. is expanding rapidly to treat cardiovascular diseases. Several studies have established that HUVECs are a highly useful model for research on human endothelium, and is effective in examining the pathophysiological mechanisms involved in the onset of CVDs.
Additionally, this approach is being increasingly incorporated in the diagnosis and treatment of various forms of cancers. Furthermore, these cells are also being incorporated in angiogenesis to study ovulation, inflammation and tumour growth patterns.
Why is India Considered a Lucrative Market for HUVEC Players?
In recent years, India has generated a fertile space for cell culture- and tissue culture-based treatment. As biotechnology acquires rapid pace in the country, numerous initiatives are being undertaken to further its applications across the broad spectrum of treatment areas.
As per data published by India Against Cancer, around 2.25 million people are afflicted with the disease, with new patients amounting to over a million every year. Hence, major companies are accelerating efforts to discover potent treatments, elevating prospects for HUVEC based treatment.
Interested to Procure The Data
How are Pooled Donor HUVECs Generating Demand?
By type, pooled donor HUVECs are acquiring significant popularity, and the segment is projected to expand at more than 10% CAGR through 2031, attributed to their ability to reduce donor variability so as to provide a uniform and consistent application standard to key genetic research platforms.
Players such as Lonza offer a series of cryopreserved HUVECs, shipped as frozen primaries, which are pooled donor and single donor based. Their XL size consists of 10 million cells/ampoule which are achieved by pooling donors.
Which is the Primary Application Area of HUVECs?
HUVECs for oncology and cancer treatment are expected to find immense applications over the decade, with the segment expected to surge ahead at 12%-15% CAGR, as prominent healthcare settings leverage the latest cell technology to eradicate the disease.
For instance, HUVEC-docetaxel (DOC) treatment has been proven to make significant breakthroughs with respect to breast cancer treatment, exhibiting more favourable anti-EMT-6 breast cancer effects in vivo.
The HUVEC landscape appears highly consolidated, marked by the presence of a handful of service providers across prominent geographies. These players primarily concentrate on offering high-grade product offerings as their primary expansion strategy.
- In December 2020, Corning Inc. launched the Corning® X-SERIES® cell processing platform which delivers fast, sterile, automated and efficient processing of human blood and blood products to obtain purified populations of immune cells for gene therapy applications
- Thermo Fisher Scientific offers the GibcoTM HUVEC Adherent Cell Culture which is cryopreserved and tested for Hepatitis B (HBV), Hepatitis C (HCV), sterility testing (bacterial & fungi), mycoplasma, HIV-1 and as a growth performance assay
*This list is indicative- full details about prominent human umbilical endothelial cells providers is available upon request.
Historical Data Available for
US$ Mn for Value & ‘000 Units for Volume
Key Regions Covered
Key Countries Covered
Key Segments Covered
Key Companies Profiled
Available upon Request
Key Market Segments Covered
- Single Donors of Human Umbilical Vein Endothelial Cells
- Pooled Donors of Human Umbilical Vein Endothelial Cells
- Human Umbilical Vein Endothelial Cells for Wound Healing
- Human Umbilical Vein Endothelial Cells for Angiogenesis
- Human Umbilical Vein Endothelial Cells for Tissue Engineering
- Human Umbilical Vein Endothelial Cells for Inflammation Treatment
- Human Umbilical Vein Endothelial Cells for Oncology
- Human Umbilical Vein Endothelial Cells for Other Applications
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Rest of MEA
- North America
- FAQs -
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
Indwelling Pleural Catheters Market research report covers detailed information on Global Indwelling...
Oncology Molecular Diagnostics Market was valued at US$ 1.7 Billion in 2020 and is anticipated to re...
Sterile Compounding Pharmacies Market is expected to reach a valuation of US$ 8.9 Billion by 2031. I...